Lentiviral Gene Therapy Against Human Immunodeficiency Virus Type 1, Using a Novel Human TRIM21-Cyclophilin A Restriction Factor

Human Gene Therapy

Volumn 23, Issue 11, 2012, Pages 1176-1185

  Chan, Emma ^a   Schaller, Torsten ^b,c   Eddaoudi, Ayad ^a   Zhan, Hong ^a   Tan, Choon Ping ^b   Jacobsen, Marianne ^a   Thrasher, Adrian J ^a   Towers, Greg J ^b   Qasim, Waseem ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHILIN A; CYCLOSPORIN; LENTIVIRUS VECTOR; NEUTRALIZING ANTIBODY; TRIPARTITE MOTIF PROTEIN 21 CYCLOPHILIN A; TRIPARTITE MOTIF PROTEIN 5; UNCLASSIFIED DRUG;

ANTIGEN ANTIBODY COMPLEX; ANTIVIRAL ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; EMBRYO; ENZYME DEGRADATION; GAMMARETROVIRUS INFECTION; GENE EXPRESSION; GENE TARGETING; GENE THERAPY; HOST CELL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; T LYMPHOCYTE; VIRAL GENE DELIVERY SYSTEM; VIRUS INHIBITION; VIRUS REPLICATION; WILD TYPE;

CARRIER PROTEINS; CELL LINE; CELL SURVIVAL; CYCLOPHILIN A; GENE EXPRESSION; GENE ORDER; GENETIC THERAPY; GENETIC VECTORS; HIV INFECTIONS; HIV-1; HUMANS; RIBONUCLEOPROTEINS; TRANSDUCTION, GENETIC; VIRUS REPLICATION;

ADENOVIRIDAE; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; LENTIVIRUS; PRIMATES;

EID: 84869007668     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2012.083     Document Type: Article

References (31)

1. Anderson, J.L., Campbell, E.M., Wu, X., et al. (2006). Proteasome inhibition reveals that a functional preintegration complex intermediate can be generated during restriction by diverse TRIM5 proteins. J. Virol. 80, 9754-9760.
2. Brennan, G., Kozyrev, Y., and Hu, S.L. (2008). TRIMCyp expression in Old World primates Macaca nemestrina and Macaca fascicularis. Proc. Natl. Acad. Sci. U.S.A. 105, 3569-3574.
3. Burbelo, P.D., Ching, K.H., Han, B.L., et al. (2010). Extraordinary antigenicity of the human Ro52 autoantigen. Am. J. Transl. Res. 2, 145-155.
4. Demaison, C., Parsley, K., Brouns, G., et al. (2002). High-level transduction and gene expression in hematopoietic repopulating cells using a human imunodeficiency virus type 1-based lentiviral vector containing an internal spleen focus forming virus promoter. Hum. Gene Ther. 13, 803-813.
5. Di, W.L., Larcher, F., Semenova, E., et al. (2011). Ex-vivo gene therapy restores LEKTI activity and corrects the architecture of Netherton syndrome-derived skin grafts. Mol. Ther. 19, 408-416.
6. Ledford, H. (2011). Targeted gene editing enters clinic. Nature 471, 16.
7. Levine, B.L., Humeau, L.M., Boyer, J., et al. (2006). Gene transfer in humans using a conditionally replicating lentiviral vector. Proc. Natl. Acad. Sci. U.S.A. 103, 17372-17377.
8. Li, X., Li, Y., Stremlau, M., et al. (2006). Functional replacement of the RING, B-box 2, and coiled-coil domains of tripartite motif 5a (TRIM5a) by heterologous TRIM domains. J. Virol. 80, 6198-6206.
9. Liao, C.H., Kuang, Y.Q., Liu, H.L., et al. (2007). A novel fusion gene, TRIM5-Cyclophilin A in the pig-tailed macaque determines its susceptibility to HIV-1 infection. AIDS 21(Suppl. 8), S19-S26.
10. Mallery, D.L., McEwan, W.A., Bidgood, S.R., et al. (2010). Antibodies mediate intracellular immunity through tripartite motif-containing 21 (TRIM21). Proc. Natl. Acad. Sci. U.S.A. 107, 19985-19990.
11. Mitsuyasu, R.T., Merigan, T.C., Carr, A., et al. (2009). Phase 2 gene therapy trial of an anti-HIV ribozyme in autologous CD34+ cells. Nat. Med. 15, 285-292.
12. Neagu, M.R., Ziegler, P., Pertel, T., et al. (2009). Potent inhibition of HIV-1 by TRIM5-cyclophilin fusion proteins engineered from human components. J. Clin. Invest. 119, 3035-3047.
13. Newman, R.M., Hall, L., Kirmaier, A., et al. (2008). Evolution of a TRIM5-CypA splice isoform in Old World monkeys. PLoS Pathogens 4, e1000003.
14. Nisole, S., Lynch, C., Stoye, J.P., and Yap,M.W. (2004). A Trim5-cyclophilin A fusion protein found in owl monkey kidney cells can restrictHIV-1. Proc.Natl.Acad. Sci. U.S.A. 101, 13324-13328.
15. Palella, F.J., Jr., Delaney, K.M., Moorman, A.C., et al.; HIV Outpatient Study Investigators. (1998). Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N. Engl. J. Med. 338, 853-860.
16. Pertel, T., Hausmann, S., Morger, D., et al. (2011). TRIM5 is an innate immune sensor for the retrovirus capsid lattice. Nature 472, 361-365.
17. Price, A.J., Marzetta, F., Lammers, M., et al. (2009). Active site remodeling switches HIV specificity of antiretroviral TRIMCyp. Nat. Struct. Mol. Biol. 16, 1036-1042.
18. Qasim, W., Mackey, T., Sinclair, J., et al. (2007). Lentiviral vectors for T-cell suicide gene therapy: Preservation of T-cell effector function after cytokine-mediated transduction. Mol. Ther. 15, 355-360.
19. Rossi, J.J., June, C.H., and Kohn, D.B. (2007). Genetic therapies against HIV. Nat. Biotechnol. 25, 1444-1454.
20. Sayah, D.M., Sokolskaja, E., Berthoux, L., and Luban, J. (2004). Cyclophilin A retrotransposition into TRIM5 explains owl monkey resistance to HIV-1. Nature 430, 569-573.
21. Schaller, T., Ylinen, L.M., Webb, B.L., et al. (2007). Fusion of cyclophilin A to Fv1 enables cyclosporine-sensitive restriction of human and feline immunodeficiency viruses. J. Virol. 81, 10055-10063.
22. Schaller, T., Ocwieja, K.E., Rasaiyaah, J., et al. (2011). HIV-1 capsid-cyclophilin interactions determine nuclear import pathway, integration targeting and replication efficiency. PLoS Pathogens 7, e1002439.
23. Stremlau, M., Owens, C.M., Perron, M.J., et al. (2004). The cytoplasmic body component TRIM5a restricts HIV-1 infection in Old World monkeys. Nature 427, 848-853.
24. Towers, G.J. (2007). The control of viral infection by tripartite motif proteins and cyclophilin A. Retrovirology 4, 40.
25. Towers, G., Collins, M., Takeuchi, Y. (2002) Abrogation of Ref1 retrovirus restriction in human cells. J Virol. 76, 2548-2550.
26. van Lunzen, J., Glaunsinger, T., Stahmer, I., et al. (2007). Transfer of autologous gene-modified T cells in HIV-infected patients with advanced immunodeficiency and drug-resistant virus. Mol. Ther. 15, 1024-1033.
27. Vink, C.A., Gaspar, H.B., Gabriel, R., et al. (2009). Sleeping beauty transposition from nonintegrating lentivirus. Mol. Ther. 17, 1197-1204.
28. Virgen, C.A., Kratovac, Z., Bieniasz, P.D., and Hatziioannou, T. (2008). Independent genesis of chimeric TRIM5-cyclophilin proteins in two primate species. Proc. Natl. Acad. Sci. U.S.A. 105, 3563-3568.
29. Wilson, S.J., Webb, B.L., Ylinen, L.M., et al. (2008a). Independent evolution of an antiviral TRIMCyp in rhesus macaques. Proc. Natl. Acad. Sci. U.S.A. 105, 3557-3562.
30. Wilson, S.J., Webb, B.L., Ylinen, L.M., et al. (2008b). Independent evolution of an antiviral TRIMCyp in rhesus macaques. Proc. Natl. Acad. Sci. U.S.A. 105, 3557-3562.
31. Wu, X., Anderson, J.L., Campbell, E.M., et al. (2006). Proteasome inhibitors uncouple rhesus TRIM5a restriction of HIV-1 reverse transcription and infection. Proc. Natl. Acad. Sci. U.S.A. 103, 7465-7470.